BACKGROUND Dysfunctional Uterine Bleeding is defined as abnormal uterine bleeding in the absence of organic disease. Regarding the medical management of DUB, several drugs have been used, however there is lack of studies suggesting the most appropriate drug. The objective of the study was to compare the two drugs, Norethisterone a progesterone derivative and Ormeloxifene, a selective oestrogen receptor modulator in terms of effectiveness and safety. MATERIALS AND METHODS Women attending Gynaec OPD s with DUB were chosen for the study. Sample size was hundred which was divided in 2 groups. Ormeloxifene 60mg twice weekly for 12 weeks followed by once a week for another 12 weeks was given in group A. Group B women received norethisterone 5mg twice a day from day 5 to day 26 of a cycle for 6 months. Primary outcome parameters noted were reduction in menstrual blood loss as measured by fall in PBAC (Pictorial Blood Loss Assessment Chart) score, increase in haemoglobin, and decrease in endometrial thickness at the end of the study. RESULTS Ormeloxifene showed a better reduction in mean PBAC score (225 to 75) compared to norethisterone (234 to 110) at 6 months (p<0.01). Similarly, group A (Ormeloxifene) showed statistically significant increase in haemoglobin concentration (7.2 g% to 10.5 g% vs. 7.6 g% to 9.9 g%, (p<0.05) and reduction in endometrial thickness from 11.8mm to 6.6mm vs. 11.2mm to 8.1mm, p<0.05, respectively, in comparison to Group B (Norethisterone). None of the cases reported any major side effects in the study. CONCLUSION Ormeloxifene is superior to norethisterone in reducing menstrual blood loss, as well as improving perimenopausal symptoms and thus in the treatment of perimenopausal DUB.

Background: Fibroid is the commonest benign tumor of the uterus and also commonest benign solid tumor in females. Fibroids are found to be 2-3 times more prevalent in obese women, specially the one’s with central obesity and in those with BMI > or = 35. Epidemiologic data also shows pregnancy is associated with reduced risk of fibroids. So, the present study will be a cross-sectional study which will be undertaken to know the association of uterine leiomyoma with BMI and parity in the women of coastal Karnataka.Methods: An analytical cross-sectional study was performed among the 100 patients attending OPD at the department of obstetrics and gynecology, Karwar institute of medical sciences from June 2018 to August 2018. Women suspected to have fibroid based on their symptoms were made to undergo ultrasonography. Comparison was made between the parity, body mass index of the patient and the size of the uterine fibroid visualized.Results: Out of 100 women studied 63 were nulliparous and 37 women were multiparous. Incidence of fibroid is inversely proportional to parity. When BMI < 18 only 6 women had fibroid, when BMI > 25, 57 women had fibroids and between 18-25 group 37 women were diagnosed with fibroid.Conclusions: The fibroid showed directly proportional association with BMI. Greater the BMI, more was the risk of fibroids. The fibroid showed inversely proportional association with parity. Greater the parity of the women lesser was her chances of being at risk of having fibroid.